Prucalopride for chronic constipation

Brian E. Lacy, Burr Loew, Michael D. Crowell

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Chronic constipation is a frequently reported medical disorder that reduces patients' quality of life and imposes a significant economic burden on the health care system. Symptoms of constipation are diverse and include infrequent bowel movements, hard stool, straining at stool, sensations of anorectal obstruction and feelings of incomplete evacuation. Patients with chronic constipation can be categorized into one of three main groups based on their underlying pathophysiology: normal transit constipation; colonic inertia; and pelvic floor dyssynergia. Specialized tests (i.e., anorectal manometry, radio-opaque marker study) may be required in some patients to help distinguish the different subtypes of constipation and to guide appropriate therapy. Although the underlying mechanism of constipation differs among patients, serotonin (5-hydroxytryptamine (5-HT)) appears to have an important role in colonic motility in some patients. Previous research has demonstrated that stimulation of 5-HT4 receptors improves symptoms of chronic constipation in some patients. Prucalopride, a selective 5-HT4 agonist, relieved symptoms of constipation in phase II and phase III clinical trials. In this monograph, we review the pharmacology, mechanism of action, efficacy and safety of the selective 5-HT4 agonist prucalopride in patients with chronic constipation.

Original languageEnglish (US)
Pages (from-to)843-854
Number of pages12
JournalDrugs of Today
Volume45
Issue number12
DOIs
StatePublished - Dec 2009

Fingerprint

prucalopride
Constipation
Serotonin 5-HT4 Receptor Agonists
Serotonin
Receptors, Serotonin, 5-HT4
Phase III Clinical Trials
Pelvic Floor
Manometry

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Lacy, B. E., Loew, B., & Crowell, M. D. (2009). Prucalopride for chronic constipation. Drugs of Today, 45(12), 843-854. https://doi.org/1396674/dot.2009.45.12.1423115

Prucalopride for chronic constipation. / Lacy, Brian E.; Loew, Burr; Crowell, Michael D.

In: Drugs of Today, Vol. 45, No. 12, 12.2009, p. 843-854.

Research output: Contribution to journalArticle

Lacy, BE, Loew, B & Crowell, MD 2009, 'Prucalopride for chronic constipation', Drugs of Today, vol. 45, no. 12, pp. 843-854. https://doi.org/1396674/dot.2009.45.12.1423115
Lacy, Brian E. ; Loew, Burr ; Crowell, Michael D. / Prucalopride for chronic constipation. In: Drugs of Today. 2009 ; Vol. 45, No. 12. pp. 843-854.
@article{a189a7ad31454277bdadca6440754f3a,
title = "Prucalopride for chronic constipation",
abstract = "Chronic constipation is a frequently reported medical disorder that reduces patients' quality of life and imposes a significant economic burden on the health care system. Symptoms of constipation are diverse and include infrequent bowel movements, hard stool, straining at stool, sensations of anorectal obstruction and feelings of incomplete evacuation. Patients with chronic constipation can be categorized into one of three main groups based on their underlying pathophysiology: normal transit constipation; colonic inertia; and pelvic floor dyssynergia. Specialized tests (i.e., anorectal manometry, radio-opaque marker study) may be required in some patients to help distinguish the different subtypes of constipation and to guide appropriate therapy. Although the underlying mechanism of constipation differs among patients, serotonin (5-hydroxytryptamine (5-HT)) appears to have an important role in colonic motility in some patients. Previous research has demonstrated that stimulation of 5-HT4 receptors improves symptoms of chronic constipation in some patients. Prucalopride, a selective 5-HT4 agonist, relieved symptoms of constipation in phase II and phase III clinical trials. In this monograph, we review the pharmacology, mechanism of action, efficacy and safety of the selective 5-HT4 agonist prucalopride in patients with chronic constipation.",
author = "Lacy, {Brian E.} and Burr Loew and Crowell, {Michael D.}",
year = "2009",
month = "12",
doi = "1396674/dot.2009.45.12.1423115",
language = "English (US)",
volume = "45",
pages = "843--854",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "12",

}

TY - JOUR

T1 - Prucalopride for chronic constipation

AU - Lacy, Brian E.

AU - Loew, Burr

AU - Crowell, Michael D.

PY - 2009/12

Y1 - 2009/12

N2 - Chronic constipation is a frequently reported medical disorder that reduces patients' quality of life and imposes a significant economic burden on the health care system. Symptoms of constipation are diverse and include infrequent bowel movements, hard stool, straining at stool, sensations of anorectal obstruction and feelings of incomplete evacuation. Patients with chronic constipation can be categorized into one of three main groups based on their underlying pathophysiology: normal transit constipation; colonic inertia; and pelvic floor dyssynergia. Specialized tests (i.e., anorectal manometry, radio-opaque marker study) may be required in some patients to help distinguish the different subtypes of constipation and to guide appropriate therapy. Although the underlying mechanism of constipation differs among patients, serotonin (5-hydroxytryptamine (5-HT)) appears to have an important role in colonic motility in some patients. Previous research has demonstrated that stimulation of 5-HT4 receptors improves symptoms of chronic constipation in some patients. Prucalopride, a selective 5-HT4 agonist, relieved symptoms of constipation in phase II and phase III clinical trials. In this monograph, we review the pharmacology, mechanism of action, efficacy and safety of the selective 5-HT4 agonist prucalopride in patients with chronic constipation.

AB - Chronic constipation is a frequently reported medical disorder that reduces patients' quality of life and imposes a significant economic burden on the health care system. Symptoms of constipation are diverse and include infrequent bowel movements, hard stool, straining at stool, sensations of anorectal obstruction and feelings of incomplete evacuation. Patients with chronic constipation can be categorized into one of three main groups based on their underlying pathophysiology: normal transit constipation; colonic inertia; and pelvic floor dyssynergia. Specialized tests (i.e., anorectal manometry, radio-opaque marker study) may be required in some patients to help distinguish the different subtypes of constipation and to guide appropriate therapy. Although the underlying mechanism of constipation differs among patients, serotonin (5-hydroxytryptamine (5-HT)) appears to have an important role in colonic motility in some patients. Previous research has demonstrated that stimulation of 5-HT4 receptors improves symptoms of chronic constipation in some patients. Prucalopride, a selective 5-HT4 agonist, relieved symptoms of constipation in phase II and phase III clinical trials. In this monograph, we review the pharmacology, mechanism of action, efficacy and safety of the selective 5-HT4 agonist prucalopride in patients with chronic constipation.

UR - http://www.scopus.com/inward/record.url?scp=77949345546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949345546&partnerID=8YFLogxK

U2 - 1396674/dot.2009.45.12.1423115

DO - 1396674/dot.2009.45.12.1423115

M3 - Article

C2 - 20135019

AN - SCOPUS:77949345546

VL - 45

SP - 843

EP - 854

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 12

ER -